We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Zynerba Pharmaceuticals, Inc in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 43 → 0 (-43)

100% less capital invested

Capital invested by funds: $14.7M → $0 (-$14.7M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 43

Holders
–
Holders Change
-43
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
43
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
-$6.25M
2
HCM
Highbridge Capital Management
New York
-$2.91M
3
YCM
Yakira Capital Management
Connecticut
-$791K
4
Renaissance Technologies
Renaissance Technologies
New York
-$772K
5
CL
CSS LLC
Illinois
-$608K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
– -$17K -13,098 Closed
BRWA
27
B. Riley Wealth Advisors
Florida
– -$16.2K -12,732 Closed
KFI
28
Key Financial Inc
Pennsylvania
– -$9.56K -7,500 Closed
NFSG
29
Newbridge Financial Services Group
Florida
– -$4.6K -3,610 Closed
TRCT
30
Tower Research Capital (TRC)
New York
– -$3.59K -2,814 Closed
Wells Fargo
31
Wells Fargo
California
– -$3.14K -2,464 Closed
FCMT
32
Founders Capital Management (Texas)
Texas
– -$2.54K -2,000 Closed
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
– -$1.02K -805 Closed
SIS
34
Sound Income Strategies
Florida
– -$445 -350 Closed
Bank of America
35
Bank of America
North Carolina
– -$360 -282 Closed
Creative Planning
36
Creative Planning
Kansas
– -$128 -100 Closed
HI
37
Harbour Investments
Wisconsin
– -$128 -100 Closed
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
– -$127 -100 Closed
HPC
39
HM Payson & Co
Maine
– -$64 -50 Closed
GIA
40
GHP Investment Advisors
Colorado
– -$2 -1 Closed
IHWM
41
Iron Horse Wealth Management
Iowa
– -$1 -1 Closed
LC
42
Lindbrook Capital
California
– -$1 -1 Closed
1
2

ZYNE Hedge Fund Activity: Q4 2023 in Review

0 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2023, worth a combined $0 — down 100% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of ZYNE and 0 opened new positions — a net loss of 43 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Beryl Capital Management, exiting entirely with an estimated $6.25M sold.

  • 0 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2023, down from 43 in Q3 2023.
  • Funds reported $0 of Zynerba Pharmaceuticals, Inc stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2023 and 43 closed out, a net change of -43 holders.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q4 2023 was Beryl Capital Management, an estimated $6.25M sold.

Based on aggregated 13F filings for Q4 2023.